Open AccessWorsening Bradycardia Following Antithymocyte Globulin Treatment of Severe Aplastic Anemia
Author(s) -
Justin Godown,
Allison M. Deal,
Kathy Riley,
Frédérique Bailliard,
Julie Blatt
Publication year - 2011
Publication title -
the journal of pediatric pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 15
eISSN - 2331-348X
pISSN - 1551-6776
DOI - 10.5863/1551-6776-16.3.218
Subject(s) - medicine , aplastic anemia , bradycardia , immunosuppression , sinus bradycardia , methylprednisolone , tacrolimus , globulin , bone marrow , transplantation , blood pressure , heart rate
Immunosuppressive regimens, which include antithymocyte globulin (ATG), are widely used for the treatment of severe aplastic anemia (SAA). However, bradycardia has been reported only as a rare side effect of ATG therapy in the manufacturer's product information and, in rare cases, in the adult literature. We present an adolescent with SAA and preexisting bradycardia who underwent immunosuppression therapy with ATG, methylprednisolone, and tacrolimus and developed profound sinus bradycardia with successive doses of ATG.